Stewart G Albert, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3660 Vista, St Louis, MO 63110 Phone: 314-977-6157 Fax: 314-977-5177 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
A Rutgers-led team has created better biosensor technology that may help lead to safe stem cell therapies for treating Alzheimer's and Parkinson's diseases and other neurological disorders.
Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announces it has licensed rights to a panel of cancer therapeutic antibodies to Peptech Limited.
When developing new medications, biologists and pharma- cologists test different active ingredients and chemical compounds. The main purpose is to find out how biological cells react to these substances.
› Verified 3 days ago